Bayer's Breakthrough: Kerendia Approved for Heart Failure in India
Bayer has received approval in India for its drug Kerendia to treat heart failure. Finerenone, already approved for CKD linked to type 2 diabetes, now addresses heart failure cases lacking effective treatments. This innovation tackles India's significant health challenges, including cardiovascular and chronic kidney diseases.
- Country:
- India
Bayer has announced an important milestone as its innovative therapy, Kerendia, secured approval from Indian regulators for treating heart failure, a significant medical challenge in the country.
Kerendia, known scientifically as finerenone, already received endorsements as a treatment for chronic kidney disease (CKD) associated with type 2 diabetes.
Expanding the use of finerenone offers a rare avenue for addressing nearly half of heart failure cases in India, marking Bayer's commitment to combating major health issues such as cardiovascular and chronic kidney diseases, noted Shweta Rai, MD of Bayer's Pharmaceutical Division in India.
Advertisement
ALSO READ
-
WHO and Bayer Renew $25M Partnership to Eliminate Neglected Tropical Diseases
-
Bayern Munich Shatters Records On and Off the Field
-
Bayern Munich Shatters Leverkusen's Unbeaten Streak with Dominant Display
-
Court Verdict: Bayer's Monsanto Faces $185 Million Reinstated Judgment
-
Bayern Munich Set to Reaffirm Dominance Amid Bundesliga Showdowns
Google News